The abstract is read at the publisher; the summary is JClub's.
Retatrutide 12 mg delivered the largest placebo-adjusted 52-week weight reduction in adults with overweight or obesity, at -19.80 percentage points (95% CrI -21.81 to -17.78).
- Why it matters: Existing obesity syntheses mainly compare drugs, leaving treatment-initiation decisions at 1 year under-evidenced, especially for dose trade-offs, discontinuation, and lifestyle support.
- What they did: The team ran a Bayesian longitudinal network meta-analysis of 180 reports from 178 randomized trials (81,014 participants), estimating treatment-policy-compatible weight change at 52 weeks and mapping which strategies had non-extrapolated 1-year evidence.
- The result: Only 78 randomisation units reached the 1-year evidence layer and 45 of 160 target strategies had non-extrapolated 52-week estimates; tirzepatide 15 mg and semaglutide 2.4 mg had high-certainty weight-loss evidence.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.